These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 16391836)

  • 21. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
    Vinodkumar CS; Kalsurmath S; Neelagund YF
    Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of Antibiotics for the Treatment of Bacteremia Due to Extended-spectrum β-Lactamase-producing Escherichia coli].
    Sugawara T; Murakami N; Uetake N; Hiraki K
    Yakugaku Zasshi; 2015; 135(6):829-33. PubMed ID: 26028418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control.
    Rodríguez-Baño J; Navarro MD; Romero L; Muniain MA; Perea EJ; Pérez-Cano R; Hernández JR; Pascual A
    Clin Infect Dis; 2006 Jan; 42(1):37-45. PubMed ID: 16323089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
    Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
    Rodriguez-Villalobos H; Malaviolle V; Frankard J; de Mendonça R; Nonhoff C; Struelens MJ
    J Antimicrob Chemother; 2006 Apr; 57(4):771-4. PubMed ID: 16501056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Nov; 29(11):1026-34. PubMed ID: 18947321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Features and Treatment Outcomes of Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131.
    Cho SY; Kang CI; Cha MK; Wi YM; Ha YE; Chung DR; Lee NY; Peck KR; Song JH;
    Microb Drug Resist; 2015 Aug; 21(4):463-9. PubMed ID: 25756854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital.
    Kaya O; Akcam FZ; Gonen I; Unal O; Ceylan T
    J Infect Dev Ctries; 2013 Jul; 7(7):507-12. PubMed ID: 23857384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bacteriophages from ExPEC Reservoirs Kill Pandemic Multidrug-Resistant Strains of Clonal Group ST131 in Animal Models of Bacteremia.
    Green SI; Kaelber JT; Ma L; Trautner BW; Ramig RF; Maresso AW
    Sci Rep; 2017 Apr; 7():46151. PubMed ID: 28401893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia.
    Martínez JA; Aguilar J; Almela M; Marco F; Soriano A; López F; Balasso V; Pozo L; Mensa J
    J Antimicrob Chemother; 2006 Nov; 58(5):1082-5. PubMed ID: 16950822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
    Xiong Z; Zhu D; Zhang Y; Wang F
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in children.
    Zaoutis TE; Goyal M; Chu JH; Coffin SE; Bell LM; Nachamkin I; McGowan KL; Bilker WB; Lautenbach E
    Pediatrics; 2005 Apr; 115(4):942-9. PubMed ID: 15805368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study.
    Apisarnthanarak A; Kiratisin P; Saifon P; Kitphati R; Dejsirilert S; Mundy LM
    Am J Infect Control; 2007 Nov; 35(9):606-12. PubMed ID: 17980240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
    Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
    J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The comparison of lytic activity of isolated phage and commercial Intesti bacteriophage on ESBL producer E. coli and determination of Ec_P6 phage efficacy with in vivo Galleria mellonella larvae model.
    Erol HB; Kaskatepe B; Ozturk S; Safi Oz Z
    Microb Pathog; 2022 Jun; 167():105563. PubMed ID: 35513294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of bla(CTX-M) beta-lactamase genes in extended-spectrum beta-lactamase producing gram-negative bacteria].
    Bayraktar B; Toksoy B; Bulut E
    Mikrobiyol Bul; 2010 Apr; 44(2):187-96. PubMed ID: 20549952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.